Skip to main content
. 2021 Mar 24;10(1):251–263. doi: 10.1007/s40120-021-00238-3

Fig. 1.

Fig. 1

The primary reason provided by nurses for discontinuation in all patients (survey round 1; n = 262) and patients who switched from an injectable DMT to peginterferon beta-1a and treatment-naive patients (survey round 2; n = 188). DMT disease-modifying therapy, FLS flu-like symptoms, ISR injection site reaction